Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company

Advancing Our Pipeline

Our strategy of prioritization and sharper scientific inquiry has yielded a focused portfolio of promising drug candidates. As of year-end 2011, the Pfizer pipeline had 90 programs in process, from Phase I through registration. These included 70 new chemical entities, 23 additional indications, 49 small molecules, 24 biologics and three vaccines in development.

View the latest pipeline on

Programs in Clinical Trial or Registration as of February 28, 2012

pipeline graphic


View our roster of new drugs that recently emerged from the pipeline.